Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Gordon, Otto"'
Autor:
Paul K. Paik, Gordon Otto, Rolf Bruns, Karl-Maria Schumacher, Karin Berghoff, Elif Sikoglu, John Heymach, Christian Britschgi, Maya Gottfried, Melissa Johnson, Frank Griesinger, Keunchil Park, Christine M. Bestvina, Jyoti D. Patel, Yuh-Min Chen, James Chih-Hsin Yang, Hye Ryun Kim, Byoung Chul Cho, Wade T. Iams, Michael Thomas, Egbert F. Smit, Julien Mazieres, Santiago Viteri, Alexis B. Cortot, Jo Raskin, Marina Chiara Garassino, Remi Veillon, Enriqueta Felip, Hiroshi Sakai, Xiuning Le
Purpose:Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non–small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups.Patients and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5552ad5b36a619d7db55e5782ec1e34c
https://doi.org/10.1158/1078-0432.c.6531026.v1
https://doi.org/10.1158/1078-0432.c.6531026.v1
Autor:
Paul K. Paik, Gordon Otto, Rolf Bruns, Karl-Maria Schumacher, Karin Berghoff, Elif Sikoglu, John Heymach, Christian Britschgi, Maya Gottfried, Melissa Johnson, Frank Griesinger, Keunchil Park, Christine M. Bestvina, Jyoti D. Patel, Yuh-Min Chen, James Chih-Hsin Yang, Hye Ryun Kim, Byoung Chul Cho, Wade T. Iams, Michael Thomas, Egbert F. Smit, Julien Mazieres, Santiago Viteri, Alexis B. Cortot, Jo Raskin, Marina Chiara Garassino, Remi Veillon, Enriqueta Felip, Hiroshi Sakai, Xiuning Le
Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019d486fdfd847164e30262bd47deff8
https://doi.org/10.1158/1078-0432.22482902.v1
https://doi.org/10.1158/1078-0432.22482902.v1
Autor:
Remi Veillon, Hiroshi Sakai, Xiuning Le, Enriqueta Felip, Alexis B. Cortot, Egbert F. Smit, Keunchil Park, Frank Griesinger, Christian Britschgi, Yi-Long Wu, Barbara Melosky, Shobhit Baijal, Gilberto de Castro Jr, Michaela Sedova, Karin Berghoff, Gordon Otto, Paul K. Paik
Publikováno v:
Scientia
Edema; Nausea; Non-small cell lung cancer Edema; Náuseas; Cáncer de pulmón de células no pequeñas Edema; Nàusees; Càncer de pulmó de cèl·lules no petites Introduction The MET inhibitor tepotinib demonstrated durable clinical activity in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8c491a32b262d254a14a8a193afbf3c
https://doi.org/10.5167/uzh-222025
https://doi.org/10.5167/uzh-222025
Autor:
Wanyuan Cui, Nick Brown, Victoria Brown, Ramesh Bulusu, Arshi Denton, Joanne Evans, Martin Forster, Dionysis Papadatos-Pastos, Loredana Pellegrino, Nessa Walsh, Rolf Bruns, Gordon Otto, Paul Paik
Publikováno v:
Lung Cancer. 165:S38-S39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0cb6dc6789a76c37adfd736effc7144
https://doi.org/10.1016/s0169-5002(22)00128-3
https://doi.org/10.1016/s0169-5002(22)00128-3
Autor:
Natasha Leighl, Christine Bestvina, Jyoti Patel, Xiuning Le, Remi Veillon, Ian Anderson, Ingel Demedts, Marina Chiara Garassino, Julien Mazières, Masahiro Morise, Egbert Smit, S Peter Eggleton, Aurora O’Brate, Gordon Otto, Rolf Bruns, Karl Maria Schumacher, Paul Paik
Publikováno v:
Neuro-Oncology Advances. 4:i22-i22
BACKGROUND Brain metastases (BMs) occur in 20–40% of patients with METex14 skipping NSCLC. Tepotinib, a highly selective MET inhibitor, demonstrated an objective response rate (ORR) of 49.1% and median duration of response (mDOR) of 13.8 months, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b544b2caac9557c5bb74828df0eb926
https://doi.org/10.1093/noajnl/vdac078.085
https://doi.org/10.1093/noajnl/vdac078.085
Autor:
Masahiro Morise, Hiroshi Sakai, Terufumi Kato, Shingo Matsumoto, Toru Kumagai, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Tomonori Hirashima, S Peter Eggleton, Rolf Bruns, Gordon Otto, Paul Paik
Publikováno v:
Annals of Oncology. 33:S475
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcd59345ac162f867d84ea10eddb3d22
https://doi.org/10.1016/j.annonc.2022.05.043
https://doi.org/10.1016/j.annonc.2022.05.043
Autor:
Marina C. Garassino, Xiuning Le, Wade T. Iam, Enriqueta Felip, Hiroshi Sakai, Remi Veillon, Egbert F. Smit, Julien Mazieres, Jo Raskin, Alexis B. Cortot, Karin Berghoff, Rolf Bruns, Gordon Otto, Paul K. Paik
Publikováno v:
Cancer Research. 82:CT536-CT536
Introduction: In the primary analysis of VISION, tepotinib — a highly selective, potent MET inhibitor — demonstrated durable efficacy, and a tolerable safety profile in patients (pts) with METex14 skipping NSCLC. We report updated outcomes, with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8094656f6bd41e84eb7bcd07fc52f180
https://doi.org/10.1158/1538-7445.am2022-ct536
https://doi.org/10.1158/1538-7445.am2022-ct536
Autor:
Khalid Abubaker, Danyi Wang, Zheng Feng, Christopher Stroh, Jiemin Liao, Gordon Otto, Juergen Scheuenpflug
Publikováno v:
Cancer Research. 82:5245-5245
Background: Anti-EGFR monoclonal antibodies are treatment options for RAS and BRAF V600 mutation-negative CRC patients. However, the literature suggests that CRC patients with sub-clonal RAS and BRAF mutations may still benefit from anti-EGFR therapi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c53ef9611fbae138c531be775e3c28f7
https://doi.org/10.1158/1538-7445.am2022-5245
https://doi.org/10.1158/1538-7445.am2022-5245
Autor:
Xiuning Le, Luis Paz-Ares, Jan Van Meerbeeck, Santiago Viteri Ramirez, Carlos Cabrera Galvez, David Vicente Baz, Young-Chul Kim, Jin-Hyoung Kang, Christopher Stroh, Dilafruz Juraeva, Rolf Bruns, Gordon Otto, Andreas Johne, Paul K. Paik
Publikováno v:
Journal of Clinical Oncology. 40:9121-9121
9121 Background: Tepotinib, a potent, highly selective, oral, MET inhibitor, showed meaningful activity in patients (pts) with NSCLC with high-level METamp by LBx in VISION. Exploratory biomarker analyses are presented herein. Methods: Pts had 0–2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f4cfbe89ec03fc04d9f429af7425971
https://doi.org/10.1200/jco.2022.40.16_suppl.9121
https://doi.org/10.1200/jco.2022.40.16_suppl.9121
Autor:
Terufumi Kato, James Chih-Hsin Yang, Myung-Ju Ahn, Hiroshi Sakai, Masahiro Morise, Yuh-Min Chen, Ji-Youn Han, Jin-Ji Yang, Jun Zhao, Jason Huang, Karin Berghoff, Rolf Bruns, Helene Vioix, Gordon Otto, Xiuning Le, Paul K. Paik
Publikováno v:
Journal of Clinical Oncology. 40:9120-9120
9120 Background: Tepotinib is a highly selective, potent MET inhibitor approved in several Asian countries for the treatment of advanced METex14 skipping NSCLC. In VISION (n=275; data cut-off: Feb 1, 2021), tepotinib had an objective response rate (O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::900f5354ab7d99984c61c0a5b5a8a3b3
https://doi.org/10.1200/jco.2022.40.16_suppl.9120
https://doi.org/10.1200/jco.2022.40.16_suppl.9120